PBS adds Ustekinumab and Omalizumab biosimilars.
From August 1, 2025, biosimilars SteQeyma (ustekinumab) has been listed on the Pharmaceutical Benefits Scheme (PBS) for some Crohn’s disease and ulcerative colitis indications. For patients living with IBD, it’s the first PBS-listed biosimilar alternative to Ustekinumab.